Background: The efficacy of therapy in cervical cancer (CESC) is blocked by high molecular heterogeneity. Thus, the sub-molecular characterization remains primarily explored for personalizing the treatment of CESC patients.
Methods: Datasets with 741 CESC patients were obtained from TCGA and GEO databases.